Laboratory values in the two cohorts of patients with COVID-19 with and without idiopathic pulmonary fibrosis (IPF) before and after propensity score matching
| Outcome | Before propensity matching | After propensity matching | ||||||||
| IPF cohort (n=251) | Non-IPF cohort (n=310 809) | P value | IPF cohort (n=251) | Non-IPF cohort (n=251) | P value | |||||
| Patients with outcome | Mean (SD) | Patients with outcome | Mean (SD) | Patients with outcome | Mean (SD) | Patients with outcome | Mean (SD) | |||
| C reactive protein (mg/L) | 80 | 70.11 (77.96) | 33 169 | 63.50 (77.20) | 0.44 | 80 | 70.11 (77.96) | 70 | 66.40 (77.49) | 0.77 |
| Lactate dehydrogenase (U/L) | 72 | 400.88 (212.88) | 26 623 | 411.63 (508.58) | 0.86 | 72 | 400.88 (212.88) | 58 | 389.78 (348.61) | 0.82 |
| Erythrocyte sedimentation rate (mm/hour) | 24 | 44.67 (31.32) | 9903 | 51.92 (32.42) | 0.27 | 24 | 44.67 (31.32) | 17 | 42.53 (31.84) | 0.83 |
| Alanine aminotransferase (U/L) | 109 | 47.84 (130.06) | 54 603 | 49.69 (155.41) | 0.90 | 109 | 47.84 (130.06) | 98 | 33.15 (39.90) | 0.28 |
| Aspartate aminotransferase (U/L) | 108 | 47.82 (103.17) | 53 037 | 57.06 (358.16) | 0.79 | 108 | 47.82 (103.17) | 96 | 36.66 (23.07) | 0.30 |
| Bilirubin (mg/dL) | 107 | 0.65 (0.53) | 54 338 | 0.63 (1.06) | 0.80 | 107 | 0.65 (0.53) | 99 | 0.59 (0.34) | 0.32 |
| Ferritin (ng/mL) | 70 | 1019.95 (1643.80) | 30 142 | 974.95 (2785.47) | 0.89 | 70 | 1019.95 (1643.80) | 62 | 688.53 (915) | 0.16 |
| Creatinine (ng/dL) | 123 | 1.47 (1.32) | 64 487 | 1.18 (1.38) | 0.02 | 123 | 1.47 (1.32) | 115 | 1.59 (1.77) | 0.56 |